Jacobs Levy Equity Management Inc. Has $637,000 Stock Position in NeuroPace, Inc. $NPCE

Jacobs Levy Equity Management Inc. lessened its holdings in shares of NeuroPace, Inc. (NASDAQ:NPCE) by 9.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 51,807 shares of the company’s stock after selling 5,289 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.16% of NeuroPace worth $637,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of NPCE. Northern Trust Corp increased its position in NeuroPace by 15.7% during the fourth quarter. Northern Trust Corp now owns 184,847 shares of the company’s stock worth $2,068,000 after buying an additional 25,035 shares during the last quarter. Jane Street Group LLC acquired a new position in NeuroPace during the fourth quarter worth approximately $1,120,000. BNP Paribas Financial Markets acquired a new position in NeuroPace during the fourth quarter worth approximately $29,000. Bank of America Corp DE increased its position in NeuroPace by 83.0% during the fourth quarter. Bank of America Corp DE now owns 24,448 shares of the company’s stock worth $274,000 after buying an additional 11,088 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in NeuroPace during the fourth quarter worth approximately $112,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Trading Down 1.5%

Shares of NASDAQ:NPCE opened at $9.86 on Friday. NeuroPace, Inc. has a 12-month low of $5.45 and a 12-month high of $18.98. The stock has a market cap of $326.17 million, a PE ratio of -11.74 and a beta of 1.90. The business has a 50 day moving average of $9.20 and a 200-day moving average of $11.16. The company has a quick ratio of 4.51, a current ratio of 5.47 and a debt-to-equity ratio of 3.02.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%.The firm had revenue of $23.52 million for the quarter, compared to the consensus estimate of $23.08 million. NeuroPace has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that NeuroPace, Inc. will post -1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on NPCE shares. Wells Fargo & Company lowered their price target on NeuroPace from $17.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Zacks Research downgraded NeuroPace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Finally, HC Wainwright assumed coverage on NeuroPace in a report on Wednesday, May 28th. They set a “buy” rating and a $18.00 price objective for the company. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.60.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.